• Azita H Talasaz, Parham Sadeghipour, Hessam Kakavand, Maryam Aghakouchakzadeh, Elaheh Kordzadeh-Kermani, Benjamin W Van Tassell, Azin Gheymati, Hamid Ariannejad, Seyed Hossein Hosseini, Sepehr Jamalkhani, Michelle Sholzberg, Manuel Monreal, David Jimenez, Gregory Piazza, Sahil A Parikh, Ajay J Kirtane, John W Eikelboom, Jean M Connors, Beverley J Hunt, Stavros V Konstantinides, Mary Cushman, Jeffrey I Weitz, Gregg W Stone, Harlan M Krumholz, Lip Gregory Y H GYH Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom; Department of Cli, Samuel Z Goldhaber, and Behnood Bikdeli.
• Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: https://twitter.com/AzitaTalasaz.
• J. Am. Coll. Cardiol. 2021 Apr 20; 77 (15): 1903-1921.

AbstractEndothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…